HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P F Searle Selected Research

tretazicar

3/2008Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
1/2008Combining gene and immunotherapy for prostate cancer.
4/2007Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
8/2005Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
7/2004Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
2/2001Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
6/2000Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
5/2000Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
1/2000Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P F Searle Research Topics

Disease

6Neoplasms (Cancer)
06/2009 - 02/2000
4Colorectal Neoplasms (Colorectal Cancer)
01/2008 - 02/2000
3Infections
10/2001 - 01/2000
2Prostatic Neoplasms (Prostate Cancer)
01/2008 - 01/2000
2Carcinoma (Carcinomatosis)
04/2007 - 06/2000
1Ovarian Neoplasms (Ovarian Cancer)
03/2008
1Colonic Neoplasms (Colon Cancer)
10/2001
1Peritoneal Neoplasms
06/2000
1Ascites
06/2000
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2000
1Hepatocellular Carcinoma (Hepatoma)
05/2000

Drug/Important Bio-Agent (IBA)

11ProdrugsIBA
06/2009 - 01/2000
9tretazicarIBA
03/2008 - 01/2000
8EnzymesIBA
06/2009 - 02/2000
5NitroreductasesIBA
01/2008 - 05/2000
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2008
1Antineoplastic Agents (Antineoplastics)IBA
07/2004
1uracil phosphoribosyltransferaseIBA
10/2001
1Flucytosine (Ancobon)FDA Link
10/2001
1Fluorouracil (Carac)FDA LinkGeneric
10/2001
1Cytosine DeaminaseIBA
10/2001
1Pharmaceutical PreparationsIBA
02/2001
1AntibodiesIBA
02/2001
1Prostate-Specific Antigen (Semenogelase)IBA
01/2000

Therapy/Procedure

5Therapeutics
06/2009 - 02/2000
2Drug Therapy (Chemotherapy)
10/2001 - 02/2001
1Immunotherapy
01/2008
1Oncolytic Virotherapy
01/2001